Centrexion Therapeutics develops non-opioid therapies for chronic pain.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/30/2019 | Series D | $90.34MM | $xx.xx | $327.06MM | New Enterprise Associates, Eli Lilly, Exome Asset Management, Quan Capital, ArrowMark Partners, Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital, Efung Capital | |
Price per Share
$xx.xx
Shares Outstanding
50,187,368
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.2x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Enterprise Associates, Eli Lilly, Exome Asset Management, Quan Capital, ArrowMark Partners, Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital, Efung Capital
|
||||||
12/30/2016 | Series C | $53.33MM | $xx.xx | $224.03MM | Interwest Partners, Kala International Investment Co., Shanghai Healthcare Industry Investment Fund | |
Price per Share
$xx.xx
Shares Outstanding
29,626,582
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.2x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Interwest Partners, Kala International Investment Co., Shanghai Healthcare Industry Investment Fund
|
||||||
11/20/2013 | Series B | $37.42MM | $xx.xx | $131.9MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
21,380,685
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.2x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
02/20/2013 | Series A | $8.75MM | $xx.xx | $43.75MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,000,000
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
0.2x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|